Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.39 |
| ▸ | CA2 | P00918 | 4/20 | 0.39 |
| ▸ | CA4 | P22748 | 4/20 | 0.39 |
| ▸ | CA9 | Q16790 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | TACR1 | P25103 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25308860 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9POLB | |
| SCHEMBL3830521 | 1.00 | CA1 (0.39) | CA1CA2CA4CA9POLB | |
| SCHEMBL28048683 | 0.86 | CA1 (0.40) | CA1CA2CA4CA9POLB | |
| SCHEMBL21354094 | 0.85 | CA1 (0.36) | CA1CA2CA4CA9CHRM1 | |
| SCHEMBL14433125 | 0.85 | CYP1A2 (0.43) | CA1CA2CA4CA9POLB | |
| SCHEMBL12439869 | 0.85 | CYP1A2 (0.43) | CA1CA2CA4CA9POLB | |
| SCHEMBL15485574 | 0.83 | CA1 (0.39) | CA1CA2CA4CA9CHRM1 | |
| SCHEMBL3832706 | 0.83 | CA1 (0.36) | CA1CA2CA4CA9CHRM1 | |
| SCHEMBL26614704 | 0.83 | CA1 (0.36) | CA1CA2CA4CA9CHRM1 | |
| SCHEMBL12491067 | 0.83 | CA1 (0.39) | CA1CA2CA4CA9CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141570-A9 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| CN-117157299-B | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2024-01-18 | — | — | US | disclosed |
| CN-117157299-A | Tricyclic heterocyclic derivative, composition and application thereof | 北京丹擎医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2023141570-A2 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF KRAS | ARVINAS OPERATIONS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| EP-3328379-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | UCB Biopharma SPRL (BE) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017020010-A1 | BIS-HETEROARYL DERIVATIVES AS MODULATORS OF PROTEIN AGGREGATION | NEUROPORE THERAPIES, INC. (US) | 2017-02-02 | — | — | WO | disclosed |
| EP-2702056-A1 | DERIVATIVES OF N- [(1H-PYRAZOL-1-YL) ARYL]- 1H - INDOLE OR 1H - INDAZOLE - 3 - CARBOXAMIDE, THEIR PREPARATION AND THEIR USE AS P2Y12 ANTAGONISTS | Sanofi (FR) | 2014-03-05 | — | — | EP | disclosed |
| EP-2518067-B1 | DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H- INDAZOLE-3-CARBOXAMIDE AND THEIR THERAPEUTIC USES AS P2Y12 ANTAGONISTS | SANOFI SA (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-8623862-B2 | Derivatives of N-[(1H-pyrazol-1-yl)aryl]-1H-indole or 1H-indazole-3-carboxamide, preparation thereof and applications thereof in therapeutics | SANOFI (FR) | 2014-01-07 | — | — | US | disclosed |
| WO-2012146318-A1 | DERIVATIVES OF N- [(1H-PYRAZOL-1-YL) ARYL] - 1H - INDOLE OR 1H - INDAZOLE - 3 - CARBOXAMIDE, THEIR PREPARATION AND THEIR USE AS P2Y12 ANTAGONISTS | SANOFI (FR) | 2012-11-01 | — | — | WO | disclosed |
| US-20120277205-A1 | DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS | SANOFI (FR) | 2012-11-01 | — | — | US | disclosed |
| EP-2518067-A1 | Derivatives of N-[(1H-pyrazol-1-YL)aryl]-1H-indole or 1H- indazole-3-carboxamide and their therapeutic uses as P2Y12 antagonists | SANOFI (FR) | 2012-10-31 | — | — | EP | disclosed |
| EP-2513110-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011073263-A1 | 1, 7 - DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-23 | — | — | WO | disclosed |
| EP-1869020-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS Corporation (US) | 2007-12-26 | — | — | EP | disclosed |
| WO-2006105262-A1 | HETEROARYL UREA DERIVATIVES USEFUL FOR INHIBITING CHKl | ICOS CORPORATION (US) | 2006-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018122-A1 | PYRIDAZINYL AMINO DERIVATIVES AS ALK5 INHIBITORS | ALK, TGFBR1, ACVR1 | CA1 4789/4885CA2 2424/4885CA4 3307/4885 |
| US-20120277205-A1 | DERIVATIVES OF N-[(1H-PYRAZOL-1-YL)ARYL]-1H-INDOLE OR 1H-INDAZOLE-3-CARBOXAMIDE, PREPARATION THEREOF AND APPLICATIONS THEREOF IN THERAPEUTICS | NTRK3, NTRK1, NTRK2 | CA1 1683/4885CA2 968/4885CA4 861/4885 |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | CA1 3060/4885CA2 3053/4885CA4 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.